

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06275-491US1	Application No. 10/567,711
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant David Cladingboel et al.	
		Filing Date February 7, 2006	Group Art Unit

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	3,464,998	09/02/1969	Krimmel			
	AB	3,471,491	10/07/1969	Venkatachala et al.			
	AC	4,751,292	06/14/1988	Fox			
	AD	5,399,564	03/21/1995	Hackler et al.			
	AE	5,804,588	09/08/1998	Dyke et al.			
	AF	6,201,024	03/13/2001	Baxter et al.			
	AG	6,242,470	06/05/2001	Baxter et al.			
	AH	6,303,659	10/16/2001	Baxter et al.			
	AI	6,492,355	12/10/2002	Alcaraz et al.			
	AJ	6,720,452	04/13/2004	Alcaraz et al.			
	AK	6,881,754	04/19/2005	Alcaraz et al.			
	AL	6,908,939	06/21/2005	Bernardon et al.			
	AM	6,927,219	08/09/2005	Duplantter et al.			
	AN	6,949,539	09/27/2005	Alcaraz et al.			
	AO	7,129,246	10/31/2006	Alcaraz et al.			
	AP	7,227,038	06/05/2007	Caffrey et al.			
	AQ	2004-0236109	11/25/2004	Van Straten et al.			
	AR	2005-0090524	04/28/2005	Ford et al.			
	AS	2006-0247257	11/02/2006	Dixon			
	AT	2007-0010497	01/11/2007	Boughton-Smith			
	AU	2007-0032465	02/08/2007	Boughton-Smith			
	AV	2007-0281931	12/06/2007	Boughton-Smith			
	AW	2007-0082930	04/12/2007	Boughton-Smith et al.			

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06275-491US1	Application No. 10/567,711
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant David Cladingboel et al.	
		Filing Date February 7, 2006	Group Art Unit

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AX	BE 650919 A	07/23/1964	Belgium			English Abstract only	
	AY	DE 1943404 A	12/17/1970	Germany			English Abstract only	
	AZ	EP 0002065	05/30/1979	Europe				
	AAA	EP 0501656 B1	09/02/1992	Europe				
	ABB	EP 0867436	09/30/1998	Europe			English Abstract only	
	ACC	EP 0940391 B1	09/08/1999	Europe				
	ADD	EP 1310493	05/14/2003	Europe				
	AEE	WO 90/10622	09/20/1990	WIPO			English Abstract	
	AFF	WO 95/04720	02/16/1995	WIPO				
	AGG	WO 97/19926	06/05/1997	WIPO				
	AHH	WO 99/26927	06/03/1999	WIPO				
	AII	WO 99/29661	06/17/1999	WIPO				
	AJJ	WO 99/18074	04/15/1999	WIPO				
	AKK	WO 00/73283	12/07/2000	WIPO				
	ALL	WO 00/75120	12/14/2000	WIPO				
	AMM	WO 01/42194	06/14/2001	WIPO				
	ANN	WO 01/44170	06/21/2001	WIPO				
	AOO	WO 02/096426	12/05/2002	WIPO				
	APP	WO 03/041707	05/22/2003	WIPO				
	AQQ	WO 03/042190	05/22/2003	WIPO				
	ARR	WO 03/080579	10/02/2003	WIPO				
	ASS	WO 2004/058270	07/15/2004	WIPO				
	ATT	WO 2004/106305	12/09/2004	WIPO				
	AUU	WO 2005/009968	02/03/2005	WIPO				
Examiner Signature				Date Considered				
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06275-491US1	Application No. 10/567,711
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant David Cladingboel et al.	
		Filing Date February 7, 2006	Group Art Unit

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AVV	WO 2006/025783	03/09/2006	WIPO				
	AWW	WO 2006/059945	06/08/2006	WIPO				

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AXX	Accession No. 2003:42109, CAS Registry No. 487064-48-2
	AYY	Alcaraz et al., "Preparation of Adamantane Derivatives as P2X7 Receptor Antagonists, CAS Accession No. 2001:904155
	AZZ	Alcaraz et al., "Novel P2X7 Receptor Antagonists" <i>Bioorganic and Medicinal Chemistry Letters</i> , 13:4043-4046 (2003)
	AAAA	Baxter et al., "Hit-to-Lead Studies: The Discovery of Potent Adamantane Amide P2X7 Receptor Antagonists," <i>Bioorganic and Medicinal Chemistry Letters</i> , 13:4047-4050 (2003)
	ABBB	Bourrie et al., "SSR125329A, A High Affinity Receptor Ligand with Potent Anti-Inflammatory Properties," <i>Eur. J. of Pharm.</i> , 456:123-131 (2002)
	ACCC	Costakis et al., "Synthesis of Some Adamantane Derivatives of 2-Aminobenzothiazoles," <i>Journal of Medicinal Chemistry</i> 14(12):1222-1223 (1971)
	ADDD	Dell'Antonio et al., "Antinociceptive effect of a new P _{2Z} /P2X7 antagonist, oxidized ATP, in arthritic rats," <i>Neuroscience Letters</i> 327:87-90 (2002)
	AEEE	Di Virgilio et al., "Purinergic P2X ₇ -Receptor: A Pivotal Role in Inflammation and Immunomodulation," <i>Drug Development Research</i> 45:207-213 (1998)
	AFFF	Ferrari et al., "Extracellular ATP Triggers IL-1 β Release by Activating the Purinergic P2Z Receptor of Human Macrophages," <i>J. Immunol.</i> 159:1451-1458 (1997)
	AGGG	Ferrari et al., "Purinergic Modulation of Interleukin-1 β Release from Microglial Cells Stimulated with Bacterial Endotoxin," <i>J. Exp. Med.</i> 185(3):579-582 (1997)
	AHHH	Goldman et al., "Valdecoxib. A COX-2 inhibitor for treatment of osteoarthritis, rheumatoid arthritis, and primary dysmenorrhea," <i>Formulary</i> 37:68-77 (2002)
	AIII	Haagsma et al., "Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled double-blind, 52 week clinical trial," <i>Br J Rheumatol</i> 36:1082-1088 (1997)
	AJJJ	Henderson et al., "Inhibition of interleukin-1-induced synovitis and articular cartilage proteoglycan loss in the rabbit knee by recombinant human interleukin-1 receptor antagonist," <i>Cytokine</i> 3(3):246-249 (1991)
	AKKK	Ho et al., "Synthesis of a Peptidomimetic Tricyclic Tetrahydrobenzo[<i>ij</i>] quinoline as a VLA-4 Antagonist," <i>J. Org. Chem.</i> 65:6743-6748, page 6745, scheme 5, (27) (2000)
	ALLL	Humphreys et al., "Modulation of P2X ₇ nucleotide receptor expression by pro-and anti-inflammatory stimuli in THP-1 monocytes," <i>Journal of Leukocyte Biology</i> 64:265-273 (1998)
	AMMM	Kadota et al., "Significance of IL-1 β and IL-1 receptor antagonist (IL-1Ra) in bronchoalveolar lavage fluid (BALF) in patients with diffuse panbronchiolitis (DPB)," <i>Clin Exp. Immunol.</i> 103:461-466 (1996)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06275-491US1	Application No. 10/567,711
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant David Cladingboel et al.	
		Filing Date February 7, 2006	Group Art Unit

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	ANNN	Khurana et al., "Clinical aspects of rheumatoid arthritis", Pathophysiology, Volume 12, Issue 3, Abstract (2005)
	AOOO	Kirkham, "Interleukin-1, Immune Activation Pathways, and Different Mechanisms in Osteoarthritis and Rheumatoid Arthritis", <i>Annals of the Rheumatic Diseases</i> , 50:395-400 (1991)
	APPP	Li et al., "Should atherosclerosis be considered a cancer of the vascular wall?" <i>Medical Hypotheses</i> , 64:694-698 (2005)
	AQQQ	Mackenzie et al., "Could rheumatoid arthritis have an infectious aetiology?" <i>Drug Discovery Today: Disease Mechanism</i> , Volume 2, Issue 3, Abstract (2005)
	ARRR	Maini et al., "Infliximab (chimeric anti-tumor necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial", <i>The Lancet</i> 354:1932-1939 (1999)
	ASSS	Modena et al., "Plant Growth Regulating Activities of 2-[2-(Arylamino)-2-oxoethyl]benzoic acids", <i>Il Farmaco</i> 48(4):567-572 (1993)
	ATTT	Ottenness et al., "Possible Role of IL-1 in Arthritis: Effects of Prostaglandins in the Regulation of IL-1 Synthesis and Actions", <i>Agent Act</i> 39 (Suppl):109-120 (1993)
	AUUU	Rains et al., "Sulfasalazine. A review of its Pharmacological Properties and Therapeutic Efficacy in the Treatment of Rheumatoid Arthritis", <i>Drugs</i> 50:137-156 (1995)
	AVVV	Richards et al., "Substituted 2-Phenyl-benzimidazole Derivatives: Novel Compounds that Suppress Key Markers of Allergy," <i>Eur. J. of Medic. Chem.</i> , 41:950-969 (2006)
	AWWW	Sakito et al., "Interleukin 1 β , Tumor Necrosis Factor Alpha, and Interleukin 8 in Bronchoalveolar Lavage Fluid of Patients with Diffuse Panbronchiolitis: A Potential Mechanism of Macrolide Therapy", <i>Respiration</i> 63:42-48 (1996)
	AXXX	Seventh International Symposium on Adenosine & Adenine Nucleotides: "Adenosin-und Purinrezeptoren als Targets neuer Arzneimittel", <i>Deutsche Apotheker Zeitung</i> 142(36):62-65 (2002)
	AYYY	Sharma et al., "Studies on Fused β -Lactams: Synthesis & Antibacterial Activity of Some Pyridyl/Quinolyl-2-azetidinones", <i>Indian Journal of Chemistry</i> 27B:494-497 (1988)
	AZZZ	Shire et al., "TNF- α inhibitors and rheumatoid arthritis", <i>Exp. Opin. Ther. Patents</i> 8(5):531-544 (1998)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	